EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance

Paula Cohen, Bronwen E Lambson, Nonhlanhla N Mkhize, Chivonne Moodley, Anna E J Yssel, Thandeka Moyo-Gwete, Talita York, Asanda Gwashu-Nyangiwe, Nonkululeko Ndabambi, Ruwayhida Thebus, Michal Juraska, Allan C deCamp und 9 weitere

Journal of Virology · 25.02.2025 · 99 (2)

DOI: 10.1128/jvi.01730-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 25.02.2025. Verfasst von Paula Cohen und 20 weiteren Autor:innen. Beteiligte Einrichtung: SA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, Sou…. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, HIV Antibodies, Drug Resistance, Viral. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against neutralization-sensitive viruses. We identified six individuals from the VRC01 treatment arm with multi-lineage breakthrough HIV-1 infections from HVTN703 , where one variant was sensitive to VRC01 (IC 50 < 25 ug/mL) but another was resistant. By comparing Env sequences of resistant and sensitive clones from each participant, we identified sites predicted to affect VRC01 neutralization and assessed the effect of their reversion in the VRC01-resistant clone on neutralization sensitivity. In four pairs, a single mutation restored partial or full sensitivity to VRC01, whereas in the fifth participant, transfer of the entire β 23-V5 loop was required. No VRC01 resistance mutations could be identified in the sixth participant, with the discordant clones differing by >100 amino acids. Mutations responsible for the differential neutralization phenotypes occurred at distinct sites across Env, including residues in loop D, the CD4-binding loop, and between the β 23 and V5 loops. Analysis of deep sequencing env data showed that VRC01 resistance was likely the property of the acquired virus, rather than occurring through post-acquisition evolution. Although VRC01-resistant parental clones generally retained sensitivity to other CD4-binding site bNAbs, they were less potently neutralized than the VRC01-sensitive clones. In conclusion, VRC01 resistance mutations occurred through multiple mutational pathways, but sensitivity to second-generation CD4bs bNAbs was retained even in VRC01-resistant transmitted viruses, confirming the potential of these bNAbs for HIV-1 prevention studies. IMPORTANCE The Antibody Mediated Prevention (AMP) trials provided proof of principle that VRC01, a CD4-binding site (CD4bs) HIV-1 broadly neutralizing antibody (bNAb), prevented the acquisition of antibody-sensitive viruses. However, understanding common mutations that confer resistance to different bNAbs provides important insights into the genetic barrier to resistance. Here we studied six AMP trial participants with breakthrough infections mediated by multiple viral lineages with discordant VRC01 sensitivity. We identified different mutations across the CD4-binding site that conferred resistance to VRC01 and showed that these mutations were a property of the acquired virus, rather than a result of post-acquisition evolution. We found that although VRC01 resistance was associated with reduced neutralization potency of second-generation CD4-binding site bNAbs, overall neutralization sensitivity was generally retained, which is promising for future use of such bNAbs in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHIV AntibodiesDrug Resistance, ViralMutationenv Gene Products, Human Immunodeficiency VirusAntibodies, MonoclonalHumansAntibodies, NeutralizingPhenotypeBroadly Neutralizing AntibodiesCD4 Antigens

Stichwörter der Autor:innen

HIV-1VRC01acquisitionbottleneckbroadly neutralizing antibodiesescape

Substanzen

HIV Antibodiesenv Gene Products, Human Immunodeficiency VirusAntibodies, NeutralizingVRC01 monoclonal antibodyBroadly Neutralizing AntibodiesAntibodies, MonoclonalCD4 Antigens

Autor:innen und Institutionen

  • SA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, South Africa.
  • Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa.
  • Division of Medical Virology and Institute of Infection Disease and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Biostatistics, University of Washington, Seattle, Washington, USA.
  • Biostatistics Division, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.

ORCID-Profile: Carolyn Williamson, Penny L Moore

Förderung

  • Gates Foundation
  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • South African Medical Research Council (SAMRC)
  • Bill and Melinda Gates Foundation

Zitieren

APA

Cohen, P., Lambson, B. E., Mkhize, N. N., Moodley, C., Yssel, A. E. J., Moyo-Gwete, T., York, T., Gwashu-Nyangiwe, A., Ndabambi, N., Thebus, R., Juraska, M., deCamp, A. C., Williamson, B. D., Magaret, C. A., Gilbert, P. B., Westfall, D., Deng, W., Mullins, J. I., Morris, L., …, & Moore, P. L. (2025). Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance. Journal of Virology, 99(2). https://doi.org/10.1128/jvi.01730-24

Vancouver

Cohen P, Lambson BE, Mkhize NN, Moodley C, Yssel AEJ, Moyo-Gwete T, et al. Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance. Journal of Virology. 2025;99(2). doi:10.1128/jvi.01730-24

BibTeX
@article{Cohen2025,
  author = {Cohen, Paula and Lambson, Bronwen E and Mkhize, Nonhlanhla N and Moodley, Chivonne and Yssel, Anna E J and Moyo-Gwete, Thandeka and York, Talita and Gwashu-Nyangiwe, Asanda and Ndabambi, Nonkululeko and Thebus, Ruwayhida and Juraska, Michal and deCamp, Allan C and Williamson, Brian D and Magaret, Craig A and Gilbert, Peter B and Westfall, Dylan and Deng, Wenjie and Mullins, James I and Morris, Lynn and Williamson, Carolyn and Moore, Penny L},
  title = {Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance},
  journal = {Journal of Virology},
  year = {2025},
  volume = {99},
  number = {2},
  doi = {10.1128/jvi.01730-24}
}
Kostenlos starten →